Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.27
NAS:CPHD's Cash-to-Debt is ranked lower than
60% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. NAS:CPHD: 1.27 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CPHD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.99  Med: 12.62 Max: 11006.5
Current: 1.27
0.99
11006.5
Equity-to-Asset 0.45
NAS:CPHD's Equity-to-Asset is ranked lower than
66% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:CPHD: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CPHD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.72 Max: 0.92
Current: 0.45
0.45
0.92
Piotroski F-Score: 6
Altman Z-Score: 5.67
Beneish M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -3.45
NAS:CPHD's Operating Margin % is ranked lower than
57% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. NAS:CPHD: -3.45 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CPHD' s Operating Margin % Range Over the Past 10 Years
Min: -34.65  Med: -6.85 Max: 1.37
Current: -3.45
-34.65
1.37
Net Margin % -6.30
NAS:CPHD's Net Margin % is ranked lower than
56% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NAS:CPHD: -6.30 )
Ranked among companies with meaningful Net Margin % only.
NAS:CPHD' s Net Margin % Range Over the Past 10 Years
Min: -29.75  Med: -9.84 Max: 0.95
Current: -6.3
-29.75
0.95
ROE % -10.03
NAS:CPHD's ROE % is ranked lower than
58% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. NAS:CPHD: -10.03 )
Ranked among companies with meaningful ROE % only.
NAS:CPHD' s ROE % Range Over the Past 10 Years
Min: -27.63  Med: -14.54 Max: 1.44
Current: -10.03
-27.63
1.44
ROA % -4.53
NAS:CPHD's ROA % is ranked lower than
53% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. NAS:CPHD: -4.53 )
Ranked among companies with meaningful ROA % only.
NAS:CPHD' s ROA % Range Over the Past 10 Years
Min: -19.19  Med: -7.46 Max: 1.04
Current: -4.53
-19.19
1.04
ROC (Joel Greenblatt) % -8.16
NAS:CPHD's ROC (Joel Greenblatt) % is ranked lower than
53% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NAS:CPHD: -8.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CPHD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -189.08  Med: -21.75 Max: 5.58
Current: -8.16
-189.08
5.58
3-Year Revenue Growth Rate 14.20
NAS:CPHD's 3-Year Revenue Growth Rate is ranked higher than
79% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NAS:CPHD: 14.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CPHD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.5  Med: 18 Max: 56.7
Current: 14.2
-15.5
56.7
3-Year EPS without NRI Growth Rate 30.70
NAS:CPHD's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NAS:CPHD: 30.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CPHD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.4  Med: -8.15 Max: 39.2
Current: 30.7
-37.4
39.2
GuruFocus has detected 4 Warning Signs with Cepheid $NAS:CPHD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CPHD's 10-Y Financials

Financials (Next Earnings Date: 2017-04-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CPHD Guru Trades in Q1 2016

Jim Simons 214,350 sh (New)
Steven Cohen 318,000 sh (New)
Manning & Napier Advisors, Inc 459,750 sh (+4.09%)
Mario Gabelli 238,500 sh (+3.02%)
PRIMECAP Management 2,407,500 sh (unchged)
Ron Baron 12,000 sh (-16.48%)
Columbia Wanger 3,789,947 sh (-29.30%)
» More
Q2 2016

CPHD Guru Trades in Q2 2016

Paul Tudor Jones 12,568 sh (New)
Manning & Napier Advisors, Inc 553,840 sh (+20.47%)
PRIMECAP Management 2,422,300 sh (+0.61%)
Mario Gabelli 238,500 sh (unchged)
Jim Simons 198,000 sh (-7.63%)
Ron Baron 8,500 sh (-29.17%)
Columbia Wanger 2,611,041 sh (-31.11%)
Steven Cohen 142,500 sh (-55.19%)
» More
Q3 2016

CPHD Guru Trades in Q3 2016

Joel Greenblatt 24,272 sh (New)
Paul Tudor Jones 280,000 sh (+2127.88%)
Jim Simons 288,500 sh (+45.71%)
Mario Gabelli 340,300 sh (+42.68%)
Manning & Napier Advisors, Inc Sold Out
Columbia Wanger Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,336,400 sh (-3.55%)
Ron Baron 3,400 sh (-60.00%)
» More
Q4 2016

CPHD Guru Trades in Q4 2016

Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Ron Baron Sold Out
Jim Simons Sold Out
PRIMECAP Management Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:PRAH, NAS:BRKR, NAS:VWR, NYSE:CRL, NAS:ICLR, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL, OTCPK:SUVPF, NAS:NEOG, NAS:INCR, NAS:EXAS, NYSE:BIO.B, OTCPK:BMXMF, NYSE:PKI, NAS:MYGN, NAS:QGEN, NAS:AXDX, NAS:FMI, NAS:VREX » details
Traded in other countries:XEP.Germany,
Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical market.

Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.

Guru Investment Theses on Cepheid

Mario Gabelli Comments on Cepheid - Jan 31, 2017

Cepheid (NASDAQ:CPHD) is a medical diagnostic and testing equipment company based in Sunnyvale, California. On September 6, 2016, Danaher agreed to acquire Cepheid for $53 cash per share, or $4 billion, in order to expand its molecular diagnostics business. The merger received the necessary regulatory and shareholder approvals and closed on November 4, 2016. The Fund earned a 6.58% annualized return.



From Mario Gabelli (Trades, Portfolio)'s ABC Fund fourth quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Baron Funds Comments on Cepheid - Feb 08, 2016

Shares of Cepheid (NASDAQ:CPHD), a provider of equipment for molecular diagnostic tests, were down in the fourth quarter. The company took down full year 2015 guidance by about 1% (excluding the effects of foreign currency), and took down longer-term operating margin guidance in 2016 and 2017. Given these moves, we sold the position. While we believe the company’s technology and reach of its products is unique, we are also mindful that it could take additional time to empirically assess the ultimate success of the expansion strategy. (Randy Gwirtzman)



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cepheid

Mario Gabelli Comments on Cepheid Guru stock highlight
Cepheid (NASDAQ:CPHD) is a medical diagnostic and testing equipment company based in Sunnyvale, California. On September 6, 2016, Danaher agreed to acquire Cepheid for $53 cash per share, or $4 billion, in order to expand its molecular diagnostics business. The merger received the necessary regulatory and shareholder approvals and closed on November 4, 2016. The Fund earned a 6.58% annualized return. Read more...
Columbia Wanger Sold 2 Stakes in September Divested holdings were in diagnostics and research industry
Columbia Wanger (Trades, Portfolio) sold two stakes from its portfolio on Sept. 30. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 111.11
CPHD's Forward PE Ratio is ranked lower than
98% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CPHD: 111.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 10.16
CPHD's PB Ratio is ranked lower than
87% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. CPHD: 10.16 )
Ranked among companies with meaningful PB Ratio only.
CPHD' s PB Ratio Range Over the Past 10 Years
Min: 2.24  Med: 8.82 Max: 14.03
Current: 10.16
2.24
14.03
PS Ratio 6.45
CPHD's PS Ratio is ranked lower than
68% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. CPHD: 6.45 )
Ranked among companies with meaningful PS Ratio only.
CPHD' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 6.7 Max: 13.36
Current: 6.45
1.76
13.36
Price-to-Operating-Cash-Flow 104.03
CPHD's Price-to-Operating-Cash-Flow is ranked lower than
96% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. CPHD: 104.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CPHD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 42.32  Med: 131.71 Max: 1895
Current: 104.03
42.32
1895
EV-to-EBITDA 219.56
CPHD's EV-to-EBITDA is ranked lower than
100% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. CPHD: 219.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPHD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16576.6  Med: -33.3 Max: 13527.9
Current: 219.56
-16576.6
13527.9
Current Ratio 4.30
CPHD's Current Ratio is ranked higher than
73% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. CPHD: 4.30 )
Ranked among companies with meaningful Current Ratio only.
CPHD' s Current Ratio Range Over the Past 10 Years
Min: 1.49  Med: 3.16 Max: 15.23
Current: 4.3
1.49
15.23
Quick Ratio 3.24
CPHD's Quick Ratio is ranked higher than
70% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. CPHD: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
CPHD' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.52 Max: 14.9
Current: 3.24
0.89
14.9
Days Inventory 183.57
CPHD's Days Inventory is ranked lower than
85% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. CPHD: 183.57 )
Ranked among companies with meaningful Days Inventory only.
CPHD' s Days Inventory Range Over the Past 10 Years
Min: 68.17  Med: 142.47 Max: 190.25
Current: 183.57
68.17
190.25
Days Sales Outstanding 50.14
CPHD's Days Sales Outstanding is ranked higher than
65% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. CPHD: 50.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.78  Med: 48.31 Max: 63.71
Current: 50.14
40.78
63.71
Days Payable 68.00
CPHD's Days Payable is ranked higher than
60% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. CPHD: 68.00 )
Ranked among companies with meaningful Days Payable only.
CPHD' s Days Payable Range Over the Past 10 Years
Min: 39.64  Med: 79.18 Max: 95.58
Current: 68
39.64
95.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
CPHD's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. CPHD: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPHD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -95.2  Med: -7.05 Max: -2.2
Current: -2.8
-95.2
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 23.74
CPHD's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.90 vs. CPHD: 23.74 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPHD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.05  Med: 17.2 Max: 50.57
Current: 23.74
2.05
50.57
Price-to-Tangible-Book 12.09
CPHD's Price-to-Tangible-Book is ranked lower than
75% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. CPHD: 12.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPHD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.85  Med: 10.56 Max: 20.59
Current: 12.09
1.85
20.59
Price-to-Intrinsic-Value-Projected-FCF 62.29
CPHD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
97% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. CPHD: 62.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPHD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 17.83  Med: 33.85 Max: 3464
Current: 62.29
17.83
3464
Price-to-Median-PS-Value 0.96
CPHD's Price-to-Median-PS-Value is ranked higher than
60% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. CPHD: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPHD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.12 Max: 4.12
Current: 0.96
0.36
4.12
Earnings Yield (Greenblatt) % -0.52
CPHD's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. CPHD: -0.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPHD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.52  Med: 0.2 Max: 0.3
Current: -0.52
-0.52
0.3

More Statistics

Revenue (TTM) (Mil) $596.3
EPS (TTM) $ -0.51
Short Percentage of Float3.34%
52-Week Range $25.09 - 53.91
Shares Outstanding (Mil)73.01

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 622 707
EPS ($) -0.20 0.48
EPS without NRI ($) -0.20 0.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Cepheid Jan 31 2017 
Mario Gabelli's ABC Fund Merger and Arbitrage 'The Deal Fund' 4th Quarter Shareholder Commentary Jan 31 2017 
Columbia Wanger Sold 2 Stakes in September Oct 07 2016 
Baron Funds Comments on Cepheid Feb 08 2016 
Columbia Wanger Ups Stake in Fiesta Restaurant Feb 01 2016 
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 

More From Other Websites
These drug and medical device companies made the most payments to L.A. hospitals Feb 14 2017
Mario Gabelli Comments on Cepheid Jan 31 2017
Mario Gabelli's ABC Fund Merger and Arbitrage 'The Deal Fund' 4th Quarter Shareholder Commentary Jan 31 2017
Behind Danaher’s 4Q16 Revenue Estimates Jan 17 2017
Here is What Hedge Funds Think About Clear Channel Outdoor Holdings, Inc. (CCO) Dec 05 2016
5 Healthcare Stocks Billionaires Are Buying Dec 05 2016
Is Chemed Corporation (CHE) Going to Burn These Hedge Funds? Dec 03 2016
Cepheid (CPHD): What Smart Money Thinks about This Stock? Nov 30 2016
CEPHEID Financials Nov 15 2016
CEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events... Nov 07 2016
Danaher Completes Acquisition Of Cepheid Nov 04 2016
Danaher Completes Acquisition Of Cepheid Nov 04 2016
CEPHEID Files SEC form 10-Q, Quarterly Report Nov 03 2016
CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers Oct 28 2016
30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US Oct 27 2016
Cepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher... Oct 24 2016
CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 24 2016
Cepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher... Oct 24 2016
Medical Product Oct 25 Earnings Roster: BAX, RMD, CPHD, EW Oct 24 2016
Danaher (DHR) Q3 Earnings Top Estimates, Revenues Up Y/Y Oct 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)